LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Assay Rapidly RSV in Children

By LabMedica International staff writers
Posted on 09 May 2017
Print article
Image: The Alere i RSV assay is designed to easily and rapidly detect respiratory syncytial virus (Photo courtesy of Alere).
Image: The Alere i RSV assay is designed to easily and rapidly detect respiratory syncytial virus (Photo courtesy of Alere).
A novel rapid assay applies a nicking-enzyme amplification reaction to easily and rapidly detect respiratory syncytial virus (RSV) in children hospitalized with acute respiratory-tract infections.

Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms and most people recover in a week or two, but RSV can be serious, especially for infants and older adults. RSV is the most important cause of acute respiratory-tract infection in neonates and young children.

Scientists at the University Hospital Heidelberg used the novel assay on 117 frozen nasopharyngeal swab samples obtained from children hospitalized with an acute respiratory-tract infection. The median age of the children whose samples were used in this study was 12 months (range: two weeks to 17.7 years).

The team used the Alere i RSV assay and correctly identified all 49 samples positive for RSV. The assay demonstrated 100% sensitivity (95% confidence interval, CI: 93% to 100%), and 97% specificity (95% CI: 89% to 100%). Testing of 65 negative samples confirmed that 63 samples were true negatives; one false-positive was incorrectly identified, and one sample was invalid. Positive test results were called after a median amplification time of 108 seconds (range: 102 to 234 seconds), with results obtained more quickly in samples with high viral load. The test results compared favorably with real-time reverse transcription polymerase chain reaction (RT-PCR) testing.

Sarah Valerie Schnee, a medical student and lead author of the study, “The total test duration, including three minutes for heating the lysis buffer, was five minutes for positive results and 13 minutes for negative results. The availability of sensitive, rapid RSV tests is critical to optimize care management, minimize unnecessary antibiotic use, and provide targeted infection control.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases on held April 22-25, 2017, in Vienna, Austria.

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.